Ratings Merus N.V.

Equities

MRUS

NL0011606264

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
57.26 ^USD	+2.54%		+7.35%	+108.22%

Jul. 08	Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate	MT
Jul. 08	Merus Initiates Mid-stage Study of Colorectal Cancer Combination Therapy	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MERUS N.V.	+108.22%	3.79B	-
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B	B+
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B	B+
ARGENX SE	+25.56%	27.95B	B
BIONTECH SE	-19.51%	20.5B	B+
GENMAB A/S	-14.36%	17.12B	A-
BEIGENE, LTD.	-15.63%	16.1B	B
WUXI APPTEC CO., LTD.	-46.67%	14.97B	A-
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B	C+
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes